PLA2G6 and diabetes mellitus: Future studies are warranted to answer these questions and whether the effect of losartan, and possibly other drugs, on reducing iPLA2 expression are a beneficial contribution to antihypertensive treatment options, especially in conjunction with disease states that have been reported to be associated with increased ceramide levels and signaling such as diabetes and obesity [30], [31].